

NOV 22 2004

## FAX TRANSMISSION

**DATE:** November 22, 2004**PTO IDENTIFIER:** Application Number 10/649,951-Conf. #6259  
Patent Number**Inventor:** Dana V. Ferraris et al.**MESSAGE TO:** US Patent and Trademark Office**FAX NUMBER:** (703) 872-9306**FROM:** CONNOLLY BOVE LODGE & HUTZ LLP

Mark J. Pino

**PHONE:** (202) 331-7111**Attorney Dkt. #:** 22227-00003-US2**PAGES (Including Cover Sheet):** 6**CONTENTS:**Certificate of Transmission (1 page); and  
Response to Election of Species Requirement (4 pages).

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (202) 331-7111 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

CONNOLLY BOVE LODGE & HUTZ LLP  
1990 M Street, N.W., Suite 800, Washington, DC 20036-3425  
Telephone: (202) 331-7111 Facsimile: (202) 293-6229

PTO/SB/97 (09-04)

Approved for use through 07/31/2006. OMB 0651-0091  
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/649,951

Attorney Docket No.: 22227-00003-US2

## Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

on November 22, 2004.  
Date

  
Signature

Mark J. Pino

Typed or printed name of person signing Certificate

43,858  
Registration Number, if applicable

(202) 331-7111  
Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Response to Election of Species Requirement (4 pages).

NOV. 22. 2004 3:53PM CBL&H 202 293 6229

RECEIVED  
CENTRAL FAX CENTER NO. 0474 P. 3

NOV 22 2004

Application No.: 10/649,951

Docket No.: 22227-00003-US2  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Dana V. Ferraris et al.

Application No.: 10/649,951

Confirmation No.: 6259

Filed: August 28, 2003

Art Unit: 1625

For: SYMMETRICALLY DISUBSTITUTED  
AROMATIC COMPOUNDS AND  
PHARMACEUTICAL COMPOSITIONS FOR  
INHIBITING POLY (ADP-RIBOSE)  
GLYCOHYDROLASE, AND METHODS FOR  
THEIR USE

Examiner: H. M. Reyes

RESPONSE TO RESTRICTION REQUIREMENT

Customer Window, MS Amendment  
U.S. Patent and Trademark Office  
220 20th Street S.  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, Virginia 22202

Dear Sir:

In response to the restriction requirement set forth in the Office Action mailed October 21, 2004, Applicants hereby traverse and provisionally elect claims 47-60 for continued examination.

REMARKS

The Examiner has restricted claims 47-60 into the following four groups (summarized):  
(I) nonheterocyclic derivatives of Formula IV; (II) heterocyclic derivatives of Formula IV; (III)


Application No.: 10/649,951

Docket No.: 22227-00003-US2  
(PATENT)

methods of using nonheterocyclic derivatives of Formula IV; and (IV) methods of using heterocyclic derivatives of Formula IV. See Restriction, pg. 2.

The groupings are justified as being distinct and unrelated because "they have different modes of operation, different functions, or different effects." Restriction, pg. 3. "In the instant case Invention I and II are unrelated because they are different inventions since each one of the said groups are drawn to compounds having a particular core per groups . . ." Restriction, pgs. 3-4.

Applicants disagree with the Examiner's description of the invention. As seen in the below Formula IV,



while each of the four groups has a particular core, it is the exact same Formula IV core in each group. The variability the Examiner apparently restricts (heterocyclic vs. nonheterocyclic) occurs at the core's outer edges, i.e., the Z substituent. Given the exactness of the core moieties, the applicants disagree the restrictions to the Z substituent render claims 47-60 unrelated for search purposes.

Moreover, each of the Formula IV compounds present in claims 47-60 are disclosed as PARG inhibitors. See Table 1, pg. 68 of the application. In other words, they function as and have the effect of PARG inhibitors. The Examiner has not pointed to anywhere in the specification where the claimed compounds "have different modes of operation, different functions, or different effects" as required under MPEP 808.01. Indeed, Comment 1 to MPEP

**Application No.: 10/649,951****Docket No.: 22227-00003-US2  
(PATENT)**

808.01 states "The form paragraph is to be used only when claims are presented to unrelated inventions, e.g., a necktie and a locomotive bearing." Applicants submit that the claimed PARG inhibitors of Formula IV are simply not independent inventions as contemplated under MPEP 808.01.

The Examiner argues that Inventions I and II are unrelated because "a reference anticipating or suggesting a given group cannot be used to reject any of the others under the meaning of 35 USC 102 or 35 USC 103." Restriction, pg. 4. This argument concerning a hypothetical piece of prior art that may or may not render one group unpatentable is irrelevant. "For the purpose of a decision on the question of restriction . . . the claims are ordinarily assume to be in proper form and patentable (novel and unobvious) over the prior art." MPEP 806.02: Patentability Over the Prior Art Not Considered.

Applicants also note that in the parent case, U.S. Application No. 09/829,827, now Patent no. 6,635,786, elected claims 93-104 to Formula VII compounds were one of eight restricted groups. Like pending claims 47-60, claims 93-104 to Formula VII compounds had an identical core moiety. And the Formula VII core moiety, similar to the Formula IV core moiety at issue, was substituted at its outer edges by a substituent ("Q") that was either a heterocyclic or nonheterocyclic variant. Unlike in the present application, however, claims 93-104 to Formula VII compounds were not further restricted in any way. Applicants believe that the precedent set by the lack of a restriction in the parent case to claims 93-104 should be followed resulting in no further restriction of claims 47-60.

For the above reasons the Examiner's four way restriction of claims 47-60 should be vacated in its entirety. Alternatively, Applicants select Group II directed to claims 47-57 and choose the species shown in claim 49 for search purposes.

Application No.: 10/649,951


Docket No.: 22227-00003-US2  
(PATENT)

Applicants believe no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 22-0185, under Order No. 22227-00003-US2 from which the undersigned is authorized to draw.

Dated: November 22, 2004

Respectfully submitted,

By:

  
Mark J. Pino, Registration No. 43,858  
CONNOLLY BOVE LODGE & HUTZ LLP  
1990 M Street, N.W., Suite 800  
Washington, DC 20036-3425  
(202) 331-7111  
(202) 293-6229 (Fax)  
Attorney for Applicants

C:\NRPonb\NDC\OK NIGHT\26811.1.DOC

4 of 4